



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

CIN. : L74899DL1978PLC009181



July 26, 2025

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Subject: Press Release for Unaudited Financial Results for quarter ended June 30, 2025

Dear Sir/ Madam,

In terms of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, please find enclosed herewith a copy of Press Release along with Investor's presentation for the Unaudited Financial results for the quarter ended June 30, 2025.

We request you to take the above on record.

Thanking you,

For Jagsonpal Pharmaceuticals Limited

Pratham Rawal
Company Secretary & Compliance Officer

Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India)
Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070



Jagsonpal Pharmaceuticals announces Q1FY26 Results

**Q1FY26 Revenue up 23% YoY to ₹756 Mn, EBITDA at ₹157 Mn
with 21% margin; PAT soars 2x to ₹108 Mn.**

Gurugram, July 26, 2025: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the unaudited financial results for the quarter ended June 30, 2025.

Rs. in Mn	Q1FY26	Q1FY25	YoY %	Q4FY25	QoQ %
Revenue	756	614	23.1%	586	29.1%
Operating EBITDA*	157	127	24.1%	97	61.9%
EBITDA Margin*	20.8%	20.6%	17 bps	16.6%	420 bps
ESOP Cost	15	24	(38.9) %	10	50.3%
PAT	108	53	562 bps	66	300 bps

**Operating EBITDA and EBITDA margins before ESOP accounting*

Q1FY26 Key Highlights:

- **Strong Growth Momentum in Q1FY26:** Reported a 23.1% YoY surge in revenue to Rs. 756 Mn, powered by sustained performance across its key brands. The company's focused brand-building strategy continued to yield results, enhancing market presence.
- **Margins Expand on Brand Strength, Profit Doubles:** Gross margins improved by 80 bps to 64.4%, backed by strong brand equity and disciplined cost management. Operating EBITDA grew 24.1% to Rs. 157 Mn, with margins at 20.8%. Net profit doubled to Rs. 108 Mn, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution.
- **Robust Cash Position:** With addition of 153 Mn of free cash during the quarter, cash position stood Rs. 1,609 Mn as of June 30, 2025 giving ample room to invest in future growth.

Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said,

“We have started FY 26 on a strong note with growth across all parameters. While our Revenue grew 23.1% to Rs. 756 Mn, operating EBITDA was at Rs. 157 Mn, up by 24.1%. The continued scale up is an outcome of our disciplined and effective execution of our strategy.

Net profit for the quarter more than doubled to Rs. 108 Mn, with addition of another Rs. 153 Mn of free cash, which stood at Rs. 1609 Mn as on 30th June 2025.

We further strengthened our position to #7 in the Gynae CVM rankings, reinforcing our leadership in the category.

We expect the growth momentum to continue as we deepen our presence in the domestic pharmaceutical market coupled with prudent use of free cash to look for a strategically suitable inorganic opportunity. “

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 1000 professionals.

The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.

For more information, please visit: www.jagsonpal.com

Company contact	Investor Relations Team
Email: cs@jagsonpal.com , Tel: +91 124 4406710 Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8 3 rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 Corporate Office: Nimai Tower, 3 rd floor, Udyog Vihar, Gurugram, Haryana – 122015	Soumya Chhaged Email- soumya@goindiaadvisors.com Mobile: +91-8619707750



Jagsonpal Pharmaceuticals Limited



FY26 Investor Presentation

July 2025



Safe Harbor



This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and several risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations.

These factors include, but not limited to: 1) change in the general market and macro-economic conditions, 2) governmental and regulatory trends, 3) successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 4) movements in currency exchange and interest rates, 5) increase in the competitive pressures and technological developments, 6) changes in the financial conditions of third parties dealing with us, 7) changes in laws and regulations that apply to our customers, suppliers and the pharmaceutical industry.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Jagsonpal Pharmaceuticals Limited may vary materially from those described in the relevant forward-looking statements.

The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation because of new information, future events or otherwise.

This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India.

Management Commentary



Manish Gupta
Managing Director

“

We have started FY 26 on a strong note with growth across all parameters. While our Revenue grew 23.1% to Rs. 756 Mn, operating EBITDA was at Rs. 157 Mn, up by 24.1%. The continued scale up is an outcome of our disciplined and effective execution of our strategy.

Net profit for the quarter more than doubled to Rs. 108 Mn, with addition of another Rs. 153 Mn of free cash, which stood at Rs. 1609 Mn as on 30th June 2025.

We further strengthened our position to #7 in the Gynae CVM rankings, reinforcing our leadership in the category.

We expect the growth momentum to continue as we deepen our presence in the domestic pharmaceutical market coupled with prudent use of free cash to look for a strategically suitable inorganic opportunity.

”

Q1FY26 Performance



Strong start to Q1FY26; PAT doubles



Healthy Sales Growth across key brands

Achieved Rs. 756 Mn in quarterly sales, marking a robust 23.1% growth compared to Q1FY25.



Strong brand equity boosting gross margins

Gross Margin increased by 80 bps to 64.4%.



Operating EBITDA up 24.1%

Op. EBITDA of Rs. 157 Mn; Margin at 20.8%, reflecting planned marketing push to support long term growth.



Profit doubles YoY on strong execution

Profit surged to Rs. 108 Mn with margins expanding by 560 bps to 14.3% - underscoring strong finish to the quarter.

Robust cash flow generation

Cash balance of Rs. 1,609 Mn as of Jun 30, 2025 - supports scaling of operations.

On course to meet annual guidance


Remains dedicated to innovation driven strategy coupled with strong inorganic capabilities along the way.

Financial Highlights: Q1FY26




(All values in Rs. Mn)

Revenue from Operations




Gross Profit & Margin (%)

■ Q1FY25




EBITDA & Margin* (%)

■ Q1FY26



PAT & Margin (%)



* EBITDA and EBITDA margin is calculated Pre-ESOP

Financial Results: Q1FY26



(All values in Rs. Mn)

Particulars	Q1FY26	Q4FY25	Q-O-Q	Q1FY25	Y-O-Y
Revenue from Operations	756	586	29.1%	614	23.1%
Total Expenses	599	489	22.6%	488	22.8%
EBITDA*	157	97	61.9%	127	24.1%
EBITDA Margin*	20.8%	16.6%	420 bps	20.6%	17 bps
Other Income	28	28	2.0%	14	95.6%
ESOP Cost	15	10	50.3%	24	(38.9)%
Depreciation	24	23	2.1%	11	119.5%
EBIT	147	92	60.1%	106	38.5%
EBIT Margin	19.4%	15.7%	380 bps	16.8%	217 bps
Finance Cost	3	3	(1.9)%	2	18.1%
Exceptional Items	-	2	(100)%	33	-
PBT	144	87	65.9%	71	103.2%
PBT Margin	19.1%	14.9%	420 bps	11.6%	750 bps
Tax (Business profits)	36	21	73.3%	18	104.3%
PAT	108	66	63.5%	53	102.8%
PAT Margin	14.3%	11.3%	300 bps	8.7%	562 bps

* EBITDA and EBITDA margin is calculated Pre-ESOP

Key Balance Sheet Items



(All values in Rs. Mn)

Particulars	30-Jun-25	31-Mar-25	QoQ	30-Jun-24	YoY
Shareholders Funds	2,535	2,399	5.7%	1,956	29.6%
Tangible Assets	6	6	(2.7)%	9	(35.1)%
Intangibles	837	856	(2.2)%	913	(8.3)%
Right of Use Assets	80	82	(2.7)%	81	(1.5)%
Assets Held for Sale	-	-	-	172	-
Financial Assets (Cash & Equivalents)	1609	1,456	10.5%	776	107.3%
Other Non-Current Assets (Net)	45	47	(4.2)%	27	66.7%
Lease liabilities	91	92	(1.1)%	87	4.6%
Net Working Capital	106	93	13.9%	168	(36.9)%

About the Company



Built for Scale. Positioned for Performance.



9.4%

Revenue CAGR (FY21-25)

27.8%

EBITDA CAGR (FY21-25)

33.8%

PAT CAGR (FY21-25)

INR 1609 Mn

Cash Balance as on Jun'25.

23% & 50%

ROCE & ROE (FY25)

13 Days

NWCC (FY25) down from 56 days in FY22

1. Therapy powerhouse with deep domain expertise

Spanning branded generics, trade generics & OTC; Ranked #8 in CVM

2. 100% India Centric Business

PAN India presence; Sub-chronic Presence

03. Lean Operations: Asset Light Model

Outsourced R&D Manufacturing; built for growth without capital strain

04. Power Brand portfolio boosting market share

Top 10 contributing 63% of sales; includes 5 #1 ranked molecules and 14 brands in the top 5.

05. Strong inorganic capabilities, supported by balance sheet

Demonstrated strategic acquisition with disciplined integration, driving profitability and margins

06. Backed by promoter conviction, long term vision

Strategic alignment towards long term value creation

Strong Presence in Key Therapies


Ranked 8th in Corporate CVM (as per CMARC RPM)

Gynecology

- 7th as per CMARC RPM in CVM
- Reaching ~90% of the Gynecologists nationwide, engagement with 35,000 out of 39,000 gynaecs.
- Leaders in Progesterone therapeutic segment

Pediatrics

- 17th as per CMARC RPM in CVM
- Maintaining regular connect with 9,700 out of 35,650 Pediatricians, ensuring ~27% coverage.
- Key segments include Gut Health (Probiotic), Cough, Cold & Fever, Anti-itch, Diarrhea and Dysentery



Orthopedics

- 2nd as per CMARC RPM in CVM
- Reaching ~80% of the Orthopedists through consistent engagement with 10,000 out of 13,000.
- Strong presence in Osteoporosis and Osteoarthritis segment.

Dermatology

- 30th as per CMARC RPM in CVM
- Operates in Demelanizing, Antifungals and Anti-histamines segments
- Regular connect with ~4,500 out of 11,500 Dermatologists in India, ensuring ~40% coverage.

Building A High-impact Asset Light Model

Capital Intensive Activities - Out-Sourced



Ideation

- In-house Ideation For Innovative Drug Concepts. 1-2 New Product Launches Every Quarter
- Focus On Mid-Sized, Sub Chronic Segment
- Aim For Substantial Market Share In Niche Segment



Research & Development

- Partner with leading CDMO players for product research and development



Contract Manufacturing

- Partner with leading Indian CMO for manufacturing



PAN-India Distribution

- 1000+ Medical Reps for brand promotion
- 18 stocking points across the country to ensure last-mile delivery



Strategic Pillars



**Innovation -
Niche Molecules,
Dominant Market
Share**

**Large, well
trained Work
Force of 1000+
Medical Reps**

**Lean Operations:
Asset Light
Model**

**Inorganic Growth
Powered by
Strategic
Acquisition**

MySakhi Initiative: Where Business Meets Social Impact



Real World Impact: Beyond The Bottom Line

Shaping the Future

Expanding outreach with self-testing kits, discounted lab tests, and an **online forum to support** women's holistic well-being.



Driving Menopause Awareness

Deliver **impactful virtual sessions** on menopause, supported by social media campaigns and community engagement.



Empowering Women Through MySakhi.in

A dedicated website offering **educational resources, health tools, and community support** focused on women's health



Transforming Hygiene Access

Built modern **sanitation complexes** across Punjab, Haryana, and Uttarakhand, fostering health and dignity for schoolgirls.




5-Year journey in a nutshell




(All values in ₹ Mn)


Revenue (Rs Mn)




Operating EBITDA (Rs Mn)*



PAT (Rs Mn)





Margins built to last



* EBITDA and EBITDA margin is calculated Pre-ESOP

Lean and Efficient Business Model



- Freeing up capital from operations to invest in growth
- Robust cash flows enabling higher distributions.
- Zero-debt and high ROCE business model supporting growth and dividends

Growth Outlook



The 3-Pronged Growth Strategy

New Product Launch

- Niche, Innovation driven
- Launch 4-6 products annually, driving market engagement and revenue

Volume Growth

- Sales Force Empowerment
- Targeted training boosts medical rep knowledge and productivity

Price Increases

- Non-NLEM Portfolio
- Competitive Pricing with Quality

Outlook - FY26 and Beyond

23%+ Revenue Growth	Q1FY26	17 bps OPM growth (Pre- ESOP)
15%+ Revenue Growth	FY26 Outlook	20%+ Operating EBITDA improvement
12-14% Revenue Growth	Beyond FY26	100-150 bps Operating margin improvement

Coupled with Inorganic strategies along the way

- Brand acquisitions in current therapies
- Business acquisition to expand therapeutic footprints



Thank You

Feel free to reach out to us if you have any questions.

JAGSONPAL PHARMACEUTICALS LTD.

Corporate Office: Nimai Tower, 3rd Floor,
Plot No. 412-415, Phase-IV, Udyog Vihar,
Gurugram -122015, Haryana (India)

Email: cs@jagsonpal.com

Website: www.jagsonpal.com

Tel No.: +91 124 4406710

INVESTOR RELATIONS

Soumya Chhajed

Email: soumya@goindiaadvisors.com

Ph: +91 8619707750